We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Genetic variation in <italic>IL28B</italic> (<italic>IFNL3</italic>) and response to interferon‐alpha treatment in myeloproliferative neoplasms.
- Authors
Lindgren, Marie; Samuelsson, Jan; Nilsson, Lars; Knutsen, Håvar; Ghanima, Waleed; Westin, Johan; Johansson, Peter L.; Andréasson, Björn
- Abstract
Abstract: Objective: In myeloproliferative neoplasms (MPN), interferon‐alpha (IFN‐α) is an effective treatment with disease‐modifying properties but currently with no clear predictors of treatment outcome. Recent genomewide association studies in chronic hepatitis C have found a strong influence of genetic polymorphism near the <italic>IL28B (IFNL3)</italic> gene in response to IFN‐α treatment. In this study, we sought to evaluate the prognostic impact of <italic>IL28B rs12979860</italic>,<italic> rs8099917,</italic> and <italic>rs12980275</italic> on IFN‐α treatment response in myeloproliferative neoplasms. Method: We retrospectively evaluated 100 patients with MPN treated with IFN‐α. The hematologic treatment response on IFN‐α was compared between patients and correlated with host genetic variations in IL28B. The genotypes of <italic>IL28B</italic> were determined by allelic discrimination assays. Results: The CC genotype of <italic>rs12979860</italic> was found significantly associated with hematologic response in polycythemia vera (PV) with a complete response (CR) in 79% (CC) compared to 48% (non‐CC), (<italic>P </italic>= .036). No association between the genotypes and treatment response on hydroxyurea was found. Conclusion: These results imply an effect of <italic>IL28B</italic> genotype on the outcome of IFN‐α treatment in MPN.
- Subjects
HUMAN genetic variation; INTERFERON alpha; MYELOPROLIFERATIVE neoplasms; GENETIC polymorphisms; ANTINEOPLASTIC agents
- Publication
European Journal of Haematology, 2018, Vol 100, Issue 5, p419
- ISSN
0902-4441
- Publication type
Article
- DOI
10.1111/ejh.13034